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ABSTRACT: Background. The role of human papillomavirus (HPV) in
oropharyngeal squamous cell cancer (SCC) has now been well estab-
lished. Clinicians’ experiences and challenges of talking to patients about
HPV have yet to be explored.
Methods. Fifteen health professionals caring for patients with oropharyn-
geal SCC were interviewed. Interviews were analyzed thematically.
Results. Participants expressed mixed views about explaining the causal
role of HPV to their patients. Normalizing HPV and emphasizing the posi-
tive prognosis associated with it were regarded as key messages to be
communicated. Challenging experiences included managing couples in a
consultation and patients’ concerns about transmitting HPV to their part-
ners. Some participants described limitations to their HPV knowledge
and identified the need for further information and training.
Conclusion. This study identified challenges experienced by health pro-
fessionals working with patients with oropharyngeal SCC and highlights
some key messages to convey to patients. Clinical guidance for health
professionals and further information for patients about HPV-positive
oropharyngeal SCC are needed. VC 2015 The Authors Head & Neck
Published by Wiley Periodicals, Inc.
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INTRODUCTION
The etiological role of human papillomavirus (HPV) in
oropharyngeal squamous cell carcinoma (SCC) has been
well established through epidemiological studies.1–4 High-
risk, sexually transmitted HPV types are thought to be
responsible for up to 5% of cancers worldwide, including
cervical, anal, penile, vaginal, vulva, and some oropha-
ryngeal cancers.5 In the United Kingdom, incidence rates
for HPV-positive oropharyngeal SCC have doubled from
1 per 100,000 to 2.3 per 100,000 in just over a decade.6
The declining incidence of HPV-negative oropharyngeal
SCC, the main risk factors for which are tobacco and
alcohol use, means that HPV-positive oropharyngeal SCC
now constitutes an increasing proportion of oropharyngeal
SCCs overall.7 HPV-positive oropharyngeal SCC seems
to be biologically and clinically distinct from other head
and neck cancers.8 Presence of HPV is associated with
improved prognosis and there is increasing interest in
de-escalating treatment in patients with HPV-positive
disease.9
In addition to differences in tumor biology and clinical
prognosis, the demographic profile of patients with HPV-
positive oropharyngeal SCC differs from those diagnosed
with HPV-negative oropharyngeal SCC. Patients with
HPV-positive oropharyngeal SCC are more likely to be
men, white, under 50 years old, married, educated, and
employed8,10 compared with their HPV-negative counter-
parts. This brings with it different treatment and rehabili-
tation needs, because patients tend otherwise to be in
good health, without any traditional risk factors or comor-
bid disorders.8
For these reasons, HPV testing has been introduced as
a clinical standard of care in oropharyngeal cancer in the
United States, under the National Comprehensive Cancer
Network guidelines.11 Testing tumors for HPV is also tak-
ing place in some United Kingdom centers, although no
specific guidelines have been published. This change in
clinical practice, together with the increasing prevalence
of HPV-positive oropharyngeal SCC, means that clini-
cians are beginning to discuss HPV with their patients
with head and neck cancer.
A diagnosis of HPV-positive oropharyngeal SCC is not
only a cancer diagnosis, with all the associated psycho-
logical implications, but also conveys the information that
the cancer was caused by a sexually transmitted infection.
The sexually transmitted nature of HPV creates a poten-
tial challenge for health professionals with little experi-
ence of discussing sexual behavior.12–14 The possible
implications of this shift were neatly summarized in a
recent editorial in the British Dental Journal: “If talking
about tobacco and alcohol habits have seemed like diffi-
cult subjects to raise, then talking about oral sex may
present a further challenge.”15 Evidence from the cervical
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cancer literature suggests that general practitioners and
practice nurses often lack knowledge of HPV and find the
topic sensitive, awkward, and difficult to explain in a
way patients can understand.16 From the patient’s per-
spective, an HPV diagnosis has the potential to cause
feelings of stigma and shame in addition to the anxiety
and health concerns usually associated with abnormal cer-
vical screening results.17 In the absence of any formal
recommendations for discussing HPV test results with
patients with oropharyngeal SCC, a recent review18 sug-
gested that the cervical cancer literature could be used to
provide a starting point.
The experiences of patients with HPV-positive oropha-
ryngeal SCC have begun to be explored; a qualitative
study with male HPV-positive oropharyngeal SCC survi-
vors in New York found that some participants were con-
cerned about infecting a partner with HPV and some had
discontinued oral sex or deep kissing even with long-term
partners. Physicians were the primary source of informa-
tion for all participants who wanted to know about HPV.19
In a small study exploring the information needs of
patients with HPV-positive oropharyngeal SCC in Texas,20
around half reported that their oncologist did not discuss
issues related to HPV with them. Many of these patients
sought information about HPV and cancer elsewhere.
It has been argued that health professionals have an
ethical obligation to ensure accuracy and transparency
when disclosing HPV as the cause of a patient’s cancer,21
but, as yet, there have been no studies exploring this
among health professionals themselves. We therefore car-
ried out an exploratory qualitative interview study with
clinicians treating patients with HPV-positive oropharyn-
geal SCC to explore their experiences and the perceived
challenges of talking to patients about HPV in this con-
text. The purpose of the study was to map a broad range
of experiences and views from professionals working
with this patient group, and seek explanations for differ-
ences in experiences, in the hope that this work would
inform future quantitative studies.
MATERIAL AND METHODS
Sample
Participants were health professionals caring for
patients with HPV-positive oropharyngeal SCC. We used
purposive sampling to recruit participants from different
disciplines in order to explore a range of perspectives.
Participants were recruited via email from 8 research-
active hospitals in England and Wales (see Table 1)
where HPV is discussed with patients. Potential partici-
pants were initially identified through existing contacts (2
surgeons and 2 oncologists) and we subsequently used
snowballing. The first author also attended multidiscipli-
nary team meetings at 2 hospitals in London to introduce
the study and recruit participants. Initially, we aimed to
purposively recruit 10 participants to include oncologists,
surgeons, and nurses as they have the most contact with
patients with HPV-positive oropharyngeal SCC. As the
study progressed, we included some additional professio-
nal groups also key to the care of patients with HPV-
positive oropharyngeal SCC, to try to maximize the range
of views. No new themes emerged from the final 3 inter-
views, suggesting saturation had been achieved. We
ceased data collection at this point and therefore no more
interviews were conducted.22 Before the interview, each
participant completed a short demographic questionnaire
and provided written informed consent. The study was
approved by the UCL Research Ethics Committee (refer-
ence number 4577/001).
Procedure
Semi-structured interviews were carried out in May and
June 2013. The interview followed a topic guide that was
developed using the existing literature on patient experi-
ences and previous work on HPV and cervical cancer. It
covered the participants’ professional background and
experience of working with patients with head and neck
cancer, and their experiences of and attitudes toward
communicating with patients about HPV-related head and
neck cancer. Suggestions for facilitating communication
in the future were also discussed.
Interviews took place face-to-face at the participant’s
workplace (n 5 7) or over the telephone (n 5 8), they
lasted 20 to 40 minutes, and were digitally recorded. All
interviews were conducted and transcribed verbatim by
the first author (R.D.).
Analysis
The interviews were analyzed using Framework Analy-
sis.23 This approach involves the organization of data into
a thematic framework that enables close inspection of the
data by theme and by participant.
Rachael Dodd familiarized herself with the interviews
by listening to, transcribing, and reading the transcripts,
making notes on recurring themes and summarizing each
interview. Themes were identified and developed into a
thematic framework with subthemes under each main
theme. Using the qualitative package NVivo 10, these
TABLE 1. Sample characteristics.
Characteristic No. of participants (n5 15)
Age [median (range)] 47 (33–59)
Sex
Male 8
Female 7
Ethnicity
White British 13
Other 2
Profession
Surgeon 5
Clinical oncologist 3
Specialist nurse 4
Research nurse 1
Specialist radiographer 1
Speech and language therapist 1
Geographic area of sample, no.
North West England 4
North East England 2
South West England 1
London 4
South East England 3
Wales 1
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data were summarized and organized into a matrix, where
each column represented a subtheme and each row repre-
sented a participant. Laura Marlow and Jo Waller read
half the transcripts each and were involved in developing
the thematic framework.24 Any disagreements in interpre-
tation were resolved by discussion.
RESULTS
We interviewed 15 clinicians from a range of professio-
nal groups. There was an even mix of male and female
health professionals, with most being from white British
backgrounds. Clinical oncologists in the United Kingdom
administer both chemotherapy and radiation. Characteris-
tics of the sample are shown in Table 1.
Significance of human papillomavirus in oropharyngeal
squamous cell carcinoma
All participants regarded the role of HPV in oropharyn-
geal SCC as an important issue, describing HPV-positive
oropharyngeal SCC as a “different disease entirely” (par-
ticipant 9, female, specialist radiographer), affecting
younger, otherwise healthy patients. The rise in incidence
was a key concern. Participants reported being able to tell
which patients had HPV because of their appearance and
demographic background, which differed from the
patients they usually treated. As one oncologist reported:
“When I first started in head and neck cancer practice,
the stereotype of the head and neck cancer patient was
pretty well fulfilled in that most of our patients were
alcohol dependent, nicotine dependent and had developed
head and neck cancer as a consequence of those two risk
factors, but we have seen a change . . . over the last . . .
decade where increasingly we’re seeing younger, non-
smoking, non-drinking patients who are on average 10
years younger and recognizing in that patient group that
their HPV associated disease is the main risk factor for
that” (participant 3, male, clinical oncologist).
The clinical implications of HPV-positive oropharyn-
geal SCC were discussed, including patients living longer
with the after-effects of treatment and patient demands
for expedited rehabilitation. One participant explained the
impact of this: “we’ve got a longer period of survivorship
for younger people who are still actively employed and
so their functional rehabilitation becomes a bigger issue
so that’s going to be a bigger part of our case load” (par-
ticipant 12, female, speech and language therapist).
Attitudes to discussing human papillomavirus
Almost all participants had talked about HPV with their
patients, but even those who did not have direct experi-
ence of this were able to express their opinions on the
issue. Views about disclosing HPV as the cause of a
patient’s cancer varied, perhaps reflecting the lack of
guidelines for discussing HPV. There was a range of
views on the possible benefits of discussing HPV status
with patients.
Participants who felt it important to discuss HPV status
believed it was “helpful for the patients’ psyche” (partici-
pant 4, male, surgeon) to understand the cause of their
cancer. Sometimes patients had done their own research
about HPV and had become “scared about it” (participant
10, female, clinical oncologist), making it important to
provide them with accurate and reassuring information. A
clinical oncologist described how patients would search
for information about HPV on the internet, and felt that
avoiding the issue in the clinic was unhelpful.
In centers running clinical trials, it was viewed as diffi-
cult not to mention HPV, because HPV status determined
eligibility that “forces the issue” (participant 2, male, sur-
geon). One reason for discussing HPV was the positive
prognosis of HPV-oropharyngeal SCC, which participants
felt had a direct impact on the patient and was seen as
“one of the major bits of information they want to know”
(participant 6, male, surgeon).
Participants who did not discuss HPV status with
patients felt it unnecessary to mention HPV because it is
“not offering a modifiable risk factor” (participant 3,
male, clinical oncologist) and focusing on the cause may
contribute to self-blame for past behavior: “When it
comes to HPV disease, I mean what can you tell them?
. . . there’s nothing that they need to adapt in their life-
style which is going to make any difference to their out-
come at all” (participant 7, male, surgeon).
One view was that patients were not concerned about
the cause of their cancer during the diagnosis consulta-
tion, where other worries and discussions about treatment
took priority: “not a single patient that I’ve met so far
has asked me what’s caused their cancer” (participant 7,
male, surgeon). It was sometimes felt to be best to “leave
it at that stage, to the patient and their family [to raise]”
(participant 1, male, surgeon) because of the fact that it
does not change the clinical management. The consulta-
tion was sometimes described as being patient-directed
and if patients did not ask about it, HPV “may just not
come up” (participant 3, male, clinical oncologist). Some
participants said they were increasingly raising the issue
of HPV with their patients, whereas others described
patient-led consultations. Mentioning clinical trials
prompted patients to ask questions, but 1 surgeon reported
“less than 10% of patients coming back at a later stage to
discuss the implications [of HPV] in a social context”
(participant 1, male, surgeon).
Variations in attitudes toward communicating about
HPV among health professionals were described, includ-
ing a difference between surgeons and clinical oncolo-
gists: “I would say the oncologists talk about it much
more easily and freely and openly, whereas the surgeons
might mention it, but they don’t go into how it’s caused,
the whole thing about HPV. No, I’d say oncologists are
better at communicating about it” (participant 8, female,
specialist nurse).
Challenges to discussing human papillomavirus
Health professionals described 2 main concerns when
talking to patients about HPV: the limitations of their
own knowledge about the virus and discomfort talking
about sexual health matters.
Knowledge. It was apparent that some of the health pro-
fessionals felt they lacked knowledge to respond to some
of the questions patients asked about HPV, with a special-
ist nurse reporting “no bottom to those questions” (partic-
ipant 11, female, specialist nurse). It appeared there was
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some uncertainty about where to find accurate informa-
tion, with consultants sometimes reported as giving differ-
ent information to that printed in journals: “he
[consultant] said ‘Oh it’s not an epidemic’ . . . am I sup-
posed to go with what he says, or am I supposed to go
with what’s in the journals?” (participant 11, female, spe-
cialist nurse). The issue was raised of not feeling well-
informed, while it was suggested that some questions are
difficult to answer because of the limits of scientific
knowledge: “they start asking questions about how I
caught HPV and when I caught it and who I caught it
from, how will I have caught it. And some of those ques-
tions are difficult to answer because we don’t have the
scientific knowledge at the moment . . . it’s still quite con-
fusing I think both for the doctors and for the patients”
(participant 5, male, clinical oncologist).
Being honest with patients about not knowing the
answers was advocated, because there is still scientific
uncertainty: “one of the questions I have been asked is ‘So
now the cancer’s gone, if I have oral sex again, is it going
to come back?’ I don’t know that answer, I don’t know if
anybody does know that answer . . . if the questions are dif-
ficult like that, I tend to say there’s a lot of research on the
go at the moment and we don’t have all the answers to the
questions” (participant 13, female, research nurse).
There was some evidence of discomfort talking about
HPV with patients. A specialist nurse said: “I’d feel out of
my depth pretty quickly if people had been on the internet
and they’d heard this and heard that” (participant 11,
female, specialist nurse). However, confidence seemed to
increase with experience, with an oncologist describing
how she felt she could now honestly say “nobody knows
the answer” (participant 10, female, clinical oncologist).
Talking about sexual health. Health professionals working
with patients with head and neck cancer are not used to dis-
cussing sexual health and some participants were very
aware of this: “You end up getting into the field of how
was the virus transmitted and you say well it’ll be broadly
speaking through sexual contact and actually it’s uncom-
mon for patients to want that spelled out, but just occasion-
ally I’ve got into a conversation between like as it were
vaginal sex, oral sex, kissing and all of that. People want it
spelled out in words of one syllable, but I think to be honest
most head and neck consultants get pretty squeamish about
that” (participant 2, male, surgeon).
Observations were raised about participants’ colleagues:
“I’m very lucky to work with some extremely talented
surgeons, . . . but I think talking about HPV takes them
out of their comfort zones somewhat . . . they are empa-
thetic enough communicators to know what they’re not
good at and I think they’d know that they’re straying out
of their comfort zone; better not to get into it” (partici-
pant 3, male, clinical oncologist).
In addition, the issue of potential blame or “finger
pointing” (participant 6, male, surgeon) in relation to sex-
ual transmission was raised. One participant observed that
“it can be particularly difficult when you have couples in a
session” (participant 12, female, speech and language ther-
apist). There were also concerns about not wanting to give
the information in the “wrong manner” and worry about
patients leaving the consultation blaming themselves. Not
all participants reported difficulties talking about sexual
matters, with the speech and language therapist being expe-
rienced in, for example, dealing with “difficult questions
about . . . engaging in sexual practice when I have a stoma”
(participant 12, female, speech and language therapist).
Dealing with the impact of human papillomavirus on
relationships
It was suggested that consultations could be influenced
by the presence of the patients’ partners and that some
patients were more open to discussion about HPV without
their partners present. For example, one couple had
researched HPV before the consultation and the partner
was concerned about whether HPV indicated infidelity:
“Both husband and wife had done their homework, they
knew about HPV, they knew he was likely to be HPV pos-
itive before the consultation started . . . but the main crux
of this issue was that . . . the wife was [saying] ‘How’s he
got it, when did he get it.’ As far as the wife was con-
cerned they’d been in a monogamous relationship for 15
years and she felt . . . this must be a sign that he’d been
unfaithful and had other partners outside of the marriage
. . . that was obviously causing some problems between the
two of them” (participant 5, male, clinical oncologist).
The techniques described below (see Key messages) for
normalizing HPV and emphasizing its high prevalence
were used to try and diffuse the issues around past and/or
present sexual activity. Clinicians often tried to help
patients realize it was not their fault and that there was
nothing they could have done to prevent their cancer.
Fear of transmission and self-blame among partners
were also described. In 1 case, a consultation had resulted
in the couple ceasing sexual activity, which had led the
clinical oncologist to re-assess how issues of sexual trans-
mission should be communicated: “we’ve been on a real
learning curve with that [discussing HPV] and I know I
got it wrong initially . . . we talked about it with a patient
and in subsequent discussions with the support workers,
that patient was not having sex with his wife anymore
because he was worried he would infect her with HPV”
(participant 3, male, clinical oncologist).
A surgeon also recognized the nature of the relationship
as important when deciding how much to discuss in the
consultation: “I was just slightly cautious . . . about dis-
cussing with partners the number of partners someone
else has had . . . because obviously it was a newer rela-
tionship, not a sort of you know, 20 years married type
one” (participant 6, male, surgeon).
The same surgeon (participant 6, male, surgeon)
described the difficulty of talking to couples when each
individual had different questions and concerns. In 1 case,
the patient was more focused on the details of the treat-
ment, but his wife was more concerned about outcome and
survival. This demonstrates the different approach health
professionals may have to take in joint consultations.
Patient concerns and questions about human
papillomavirus
Almost all participants gave examples of concerns and
questions patients had expressed about HPV. Views
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differed among health professionals about what patients’
primary concerns were. Some participants reported con-
cerns mainly about diagnosis and treatment; with others
reporting concerns and questions about HPV and trans-
mission (see previous section). One specialist nurse
reported an experience with a patient worried about
transmitting HPV to his wife and re-infecting himself if
he continued to practice oral sex. This patient was also
worried about his son and talked about getting him vac-
cinated: “I had this one guy who was HPV positive and
obviously he was really worried about passing this onto
his wife or being re-infected by HPV if he continued to
practice oral sex. . . He also was really worried about his
son . . . because he knew that girls are being vaccinated
against the HPV virus. He was worried that his genetic
makeup, that he’s developed a cancer by the HPV
virus, that his son was going to and he was looking into
getting his son vaccinated privately” (participant 15,
female, specialist nurse).
Specialist nurses described how some patients “come
armed with” (participant 8, female, specialist nurse) lots
of questions about implications for transmission and the
chances of becoming re-infected, but also noted that
others “probably wouldn’t ask many questions” (partici-
pant 11, female, specialist nurse). Some nurses thought
that patients felt more comfortable asking them questions
than the surgeon or clinical oncologist. This was acknowl-
edged by some surgeons who said that it was the special-
ist nurses who were asked follow-up questions. Nurses
and allied health professionals tended to see it as their
role to be “the patients’ advocate” (participant 8, female,
specialist nurse), checking whether they had any ques-
tions after the consultation.
Key messages
Several key messages about HPV were highlighted by
participants, suggesting an agreement about core mes-
sages perceived to be useful to the patient. These focused
on trying to minimize possible negative psychological
responses to HPV and presenting the diagnosis in a way
that was easy to understand and emphasized its positive
implications. Recognizing the amount of information each
patient could understand and tailoring communication to
avoid overloading them was mentioned by participants as
important. It was suggested that delivering information
about HPV in a factual manner “can distance any emotive
element” (participant 12, female, speech and language
therapist), with the aim of “not making a big deal of it”
(participant 10, female, clinical oncologist).
Normalizing human papillomavirus. Participants reported a
range of ways they would try to normalize HPV infection
and reduce its psychological impact. This included
describing the high prevalence of HPV, highlighting that
transmission is through normal sexual behavior, and using
the context of cervical cancer and HPV vaccination.
High prevalence. HPV was often normalized by explain-
ing that anyone who is sexually active will have been
exposed to it: “it’s just really a difference between how
the body deals with it in different people” (participant 4,
male, surgeon). The importance of communicating the
fact that HPV is “a ubiquitous problem” (participant 5,
male, clinical oncologist) was emphasized; a surgeon
reported telling his patients that HPV is as common as
flu, calling it “genital flu” (participant 6, male, surgeon).
Normal sexual behavior. Participants emphasized that HPV
was caused by normal sexual behavior and was not an
indication that the patient was promiscuous: “this is
something which is associated with probably any sexual
relationship . . . it’s not like getting a dose of gonorrhea
or chlamydia” (participant 4, male, surgeon). It was sug-
gested that by being deliberately vague about the nature
of transmission, it was possible to reassure the patient
that almost anything could have caused it: “I say you can
get it from kissing somebody . . . that may not be the
most common way to get it but you could” (participant 5,
male, clinical oncologist). Participants also emphasized
the fact that HPV is an infection likely to have occurred
a long time ago and that the patient had “not gone out
and slept with an infected individual” (participant 4,
male, surgeon).
Link with cervical cancer/human papillomavirus vaccination.
Referring to HPV in the context of cervical cancer was
reported to help patients understand that the same virus is
involved in both cancers. Mentioning the HPV vaccina-
tion program was thought to convey to the patient that
this virus “isn’t something special” (participant 3, male,
clinical oncologist) and 1 surgeon described how he
would explain this: “I always explain that it’s the same
virus that’s related to cervical cancer and that anyone
that’s sexual active will have been exposed to it, hence
the vaccination program for pre-sexually active individu-
als” (participant 4, male, surgeon).
No need to change behavior. When patients were con-
cerned that they had “caused” their cancer, participants
reassured them that there was no need to modify their
behavior. Participants explained how they would tell
patients with cancer related to tobacco and alcohol use to
change their behavior as this was important for their
prognosis, whereas for patients with HPV-positive oro-
pharyngeal SCC “there’s no change in their behavior
related to the sexual practice right now that you’re advis-
ing them to take” (participant 2, male, surgeon), as this
would not affect the outcome.
Positive prognosis. Participants tried to convey the posi-
tive prognosis of HPV-positive oropharyngeal SCC, with
1 clinical oncologist reporting how this information is
useful: “I think where knowledge of HPV status is useful
to the patient, is enabling them to understand yes you’ve
got head and neck cancer but we know that this particular
head and neck cancer carries a much better prognosis
than other forms of head and neck cancer” (participant 3,
male, clinical oncologist).
Conveying the message about prognosis was viewed by
most of the health professionals to help counter any feel-
ings of blame and guilt among patients seeing this as “a
bit of good news for them” (participant 7, male, surgeon)
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and was sometimes accompanied by a comparison to
head and neck cancer related to smoking and other risk
factors, using terms such as doing “better in the long
term” (participant 4, male, surgeon) and a “better
prognosis” (participant 6, male, surgeon).
Professional development
Learning from experience. As health professionals saw an
increasing number of HPV-positive oropharyngeal SCC
cases, they felt they had begun to learn what is relevant
for patients. One clinical oncologist described how in the
past he had “mentioned unnecessarily orogenital transmis-
sion and that’s not actually relevant” (participant 3, male,
clinical oncologist).
A transition was evident, from participants previously
talking about contracting HPV through oral sexual behav-
iors, to now talking about most sexually active people
contracting HPV. In some cases, participants reported
having identified areas of discussion they avoided because
of their lack of knowledge. They had since made an effort
to find out more, resulting in increased confidence and
more open discussions about HPV. Knowing the latest
research and reading the literature was of upmost impor-
tance: “I mean for us it was finding out more information
and having the knowledge to answer questions . . . then
also just learning from experience about the types of
things that people are asking, . . . doing your best to find
out what the answer to that question is for the next person
to ask. Because if one’s [patient] going to ask, the next
are” (participant 15, female, specialist nurse).
Learning from others. Regular team updates and feedback
with colleagues were mentioned as useful to improve dis-
semination of information to the patient in the future. It
was acknowledged that colleagues “think differently”
(participant 1, male, surgeon) so working as a multidisci-
plinary team was viewed as very important. Attending
conferences was also perceived as a valuable way to both
increase knowledge about the area and learn alternative
ways to discuss HPV-positive oropharyngeal SCC.
There was agreement over the need to add to and pro-
vide consistent information to patients with HPV-positive
oropharyngeal SCC: “incorporating it in our . . . patient
information . . . I certainly think that there will be serious
room for improvement in that” (participant 14, male, spe-
cialist nurse).
It was also suggested that a leaflet and/or guidelines
offering advice for health professionals would be useful.
Another suggestion was learning from colleagues working
in cervical cancer, as they have “done a very good job in
that women with cervix cancer don’t get immediately
vilified for being sexually promiscuous and that’s not the
public conception of cervix cancer” (participant 5, male,
clinical oncologist).
Training. Communication workshops and training were
mentioned as a way of developing further skills: “we
would be best off receiving some degree of training in
terms of how to communicate this information to
patients” (participant 7, male, surgeon). In some centers,
communication workshops had already been carried out
and participants from these centers felt they had
benefited.
DISCUSSION
This is the first study to explore the views and experi-
ences of health professionals talking to patients about
HPV in the context of oropharyngeal SCC. Views about
discussing patients’ HPV status were mixed. Some felt it
was beneficial for the patient to know the cause of their
cancer, others felt that as clinical management is not cur-
rently determined by HPV status, discussing HPV in con-
sultations was not necessary. Most health professionals in
this sample did talk to their patients about HPV, with dis-
cussions sometimes initiated by the health professional
and sometimes by the patient.
Participants described several key messages about HPV
that they felt were important to incorporate into their dis-
cussions with patients. Describing the high prevalence of
HPV and its link with normal sexual behavior, and
explaining HPV using the context of cervical cancer and
HPV vaccination helped to normalize the infection. Dis-
cussion of oral sex specifically was deemed unhelpful,
and recent United Kingdom evidence confirms that oral
sex is commonplace, with the majority of people report-
ing oral sexual contact in the last year, and numbers ris-
ing in younger age groups.25 In the cervical cancer
literature, the high prevalence of HPV has been an impor-
tant message to convey to patients and has been shown to
reduce stigma and embarrassment.17,26 Previous literature
has suggested because of a lack of research regarding the
psychosocial impact of HPV on patients with oropharyn-
geal SCC, that it is helpful to look to the counseling mes-
sages used in the cervical cancer literature,18,27 although
the psychosocial implications for patients with HPV-
positive oropharyngeal SCC may be different. Our partici-
pants also felt it was important to explain that HPV-
positive oropharyngeal SCC tends to have a positive
prognosis. Qualitative work with patients with HPV-
positive oropharyngeal SCC suggests that they are
encouraged by this information,19 supporting this as a key
message for health professionals to convey. A potential
implication of explaining the good survival rates to
patients with HPV-positive oropharyngeal SCC is a
resulting preference for de-escalation of treatment, as 1
surgeon described. Ongoing clinical trials9 are exploring
the possibility of de-escalating treatment for HPV-
oropharyngeal SCC, and once the results of these trials
are published clinical guidelines should be available.
Until then, health professionals may still need to be pre-
pared for conversations about de-escalating treatment,
especially with highly informed patients.
Qualitative work with patients with HPV-positive oro-
pharyngeal SCC suggests that questions about HPV are
overshadowed by concerns about cancer.19 Some of the
nurses that we interviewed described a lack of confidence
answering questions about HPV largely because of their
own lack of knowledge. Given that nurses are often the
first point of contact for patients with questions, it is
important that information and training is available to
increase their knowledge and improve their confidence
for these discussions. Surgeons and clinical oncologists
also felt there was a general lack of knowledge about
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HPV and oropharyngeal SCC, but understood this was
due to limited scientific knowledge and were generally
confident explaining this to patients. Most of the health
professionals we interviewed felt that additional training
could help them improve their knowledge about HPV and
communication with their patients with HPV-positive oro-
pharyngeal SCC, supporting previous research with den-
tists and dental hygienists.12 Some of the participants we
interviewed felt that communicating with patients with
HPV-positive head and neck cancer was very different
from communicating with patients whose cancer was
related to tobacco and alcohol use. Patients with HPV-
positive oropharyngeal SCC would usually be given more
information about the cause of their cancer and this often
brought with it the need to discuss sexual behavior. These
discussions have the potential to cause problems in rela-
tionships, demonstrated by some of the cases described in
this study and previous findings from Baxi et al.19 This
should therefore be something health professionals con-
sider when planning treatment and recommending support
for patients.
The findings from this study mirror those of similar stud-
ies in the cervical cancer literature.16 This suggests signifi-
cant overlap in the concerns of health professionals from
the 2 fields. Research into common questions asked by
patients28,29 and educational needs of health professionals
from the cervical cancer literature30 could therefore be use-
ful to head and neck cancer clinicians. It is important to
consider, however, that the needs and concerns of patients
with HPV-positive oropharyngeal SCC are likely to differ
from those of patients with cervical cancer because, in part,
to that fact that a high proportion of patients with HPV-
positive oropharyngeal SCC are men.6,31
We sampled a range of health professionals across Eng-
land and Wales to gain perspectives on communicating
about HPV-positive oropharyngeal SCC from different dis-
ciplines. This work offers a useful starting point, which
could contribute to the development of information for
health professionals and potentially inform larger quantita-
tive work with patients with HPV-positive oropharyngeal
SCC, with the ultimate goal of developing information for
patients. Conducting this study using qualitative methods
enabled the complexities of the consultation to be dis-
cussed; however, we acknowledge a number of limitations
to the study. The health professionals in this study may
have been those who are more comfortable talking about
HPV, so it is possible that additional themes may have
arisen in those who do not talk about HPV, as these were
difficult to sample. Participants may also have personal
biases, which could influence the discussion of sensitive
topics, such as sexually transmitted infections. We were not
able to draw comparisons between the different professional
groups because of small numbers, but this could be an
important avenue of future research. Patients’ views were
not explored in this study, so caution is also needed when
interpreting the data about patients’ concerns, as these are
all from the perspective of the health professionals.
The demographic characteristics of patients with HPV-
positive oropharyngeal SCC present new challenges for
health professionals in terms of the questions being asked,
the factors important to the patients, and their rehabilita-
tion and treatment needs. Experiences among health pro-
fessionals differed, suggesting a need for clinical
guidance for communication about HPV in this context to
ensure that patients are receiving consistent messages.
Further research is needed with patients to explore what
being diagnosed with HPV-positive oropharyngeal SCC
means for them. There is a wealth of information avail-
able in the cervical cancer literature that could be usefully
adapted for health professionals caring for patients with
HPV-positive oropharyngeal SCC.
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